{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:12:03Z","timestamp":1788567123245,"version":"build-2803163510"},"reference-count":64,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370164"],"award-info":[{"award-number":["82370164"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82202579"],"award-info":[{"award-number":["82202579"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372312"],"award-info":[{"award-number":["82372312"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010877","name":"Shenzhen Science and Technology Innovation Committee","doi-asserted-by":"publisher","award":["JCYJ20230807110419040"],"award-info":[{"award-number":["JCYJ20230807110419040"]}],"id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010877","name":"Shenzhen Science and Technology Innovation Committee","doi-asserted-by":"publisher","award":["JCYJ20240813150301002"],"award-info":[{"award-number":["JCYJ20240813150301002"]}],"id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010877","name":"Shenzhen Science and Technology Innovation Committee","doi-asserted-by":"publisher","award":["JCYJ20240813150249043"],"award-info":[{"award-number":["JCYJ20240813150249043"]}],"id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010877","name":"Shenzhen Science and Technology Innovation Committee","doi-asserted-by":"publisher","award":["JCYJ20220530144814032"],"award-info":[{"award-number":["JCYJ20220530144814032"]}],"id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.xcrm.2025.102365","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T09:26:14Z","timestamp":1758619574000},"page":"102365","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["FLT3L-based drug conjugate effectively targets chemoresistant leukemia stem cells in acute myeloid leukemia"],"prefix":"10.1016","volume":"6","author":[{"given":"Dengyang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuting","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Kong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kam Tong","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhizhuang Joe","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8348-8755","authenticated-orcid":false,"given":"Yun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2025.102365_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.10","article-title":"Acute myeloid leukaemia","volume":"2","author":"Khwaja","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.xcrm.2025.102365_bib2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.xcrm.2025.102365_bib3","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1080\/14712598.2020.1817373","article-title":"Brief overview of antibody-drug conjugate therapy for acute leukemia","volume":"21","author":"Walter","year":"2021","journal-title":"Expert Opin Biol Th"},{"key":"10.1016\/j.xcrm.2025.102365_bib4","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1182\/blood.V126.23.1366.1366","article-title":"IMGN779, a CD33-Targeted Antibody-Drug Conjugate (ADC) with a Novel DNA-Alkylating Effector Molecule, Induces DNA Damage, Cell Cycle Arrest, and Apoptosis in AML Cells","volume":"126","author":"Krystal","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102365_bib5","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1182\/blood.2021015246","article-title":"Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML","volume":"141","author":"Roas","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102365_bib6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/bjh.12750","article-title":"Prognostic factors for acute myeloid leukaemia in adults \u2013 biological significance and clinical use","volume":"165","author":"Liersch","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.xcrm.2025.102365_bib7","article-title":"FLT3-TKD in the prognosis of patients with acute myeloid leukemia: A meta-analysis","volume":"13","author":"Li","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2025.102365_bib8","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40364-020-00210-7","article-title":"Development of a highly sensitive method for detection of FLT3D835Y","volume":"8","author":"Guo","year":"2020","journal-title":"Biomark. Res."},{"key":"10.1016\/j.xcrm.2025.102365_bib9","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41408-021-00495-3","article-title":"FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm","volume":"11","author":"Daver","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.xcrm.2025.102365_bib10","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1038\/onc.2015.362","article-title":"Identification of an orally available compound with potent and broad FLT3 inhibition activity","volume":"35","author":"Chen","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.xcrm.2025.102365_bib11","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1756-8722-5-72","article-title":"SU11652 Inhibits tyrosine kinase activity of FLT3 and growth of MV-4-11 cells","volume":"5","author":"Guo","year":"2012","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2025.102365_bib12","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","article-title":"The roles of FLT3 in hematopoiesis and leukemia","volume":"100","author":"Gilliland","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102365_bib13","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1158\/0008-5472.CAN-06-0018","article-title":"IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic\/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples","volume":"66","author":"Piloto","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102365_bib14","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-021-00484-2","article-title":"The clinical development of antibody\u2013drug conjugates \u2014 lessons from leukaemia","volume":"18","author":"Jabbour","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102365_bib15","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.18632\/oncotarget.28331","article-title":"Anti-tumor effect of antibody drug conjugate ASP1235 targeting Fms-like tyrosine kinase 3 with venetoclax plus azacitidine in an acute myeloid leukemia xenograft mouse model","volume":"13","author":"Tsuzuki","year":"2022","journal-title":"Oncotarget"},{"key":"10.1016\/j.xcrm.2025.102365_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2025.107690","article-title":"Safety, tolerability, and pharmacokinetics of ASP1235 in relapsed or refractory acute myeloid leukemia: A phase 1 study","volume":"152","author":"Al Malki","year":"2025","journal-title":"Leuk. Res."},{"key":"10.1016\/j.xcrm.2025.102365_bib17","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41568-020-0263-0","article-title":"The dormant cancer cell life cycle","volume":"20","author":"Phan","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2025.102365_bib18","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.780.780","article-title":"Human AML stem cells remain quiescent and exhibit chemotherapy resistance within the bone marrow endosteal region","volume":"110","author":"Saito","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102365_bib19","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1158\/2159-8290.CD-20-1375","article-title":"Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence","volume":"11","author":"Duy","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2025.102365_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12040822","article-title":"Therapy-Induced Senescence: An \"Old\" Friend Becomes the Enemy","volume":"12","author":"Saleh","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.xcrm.2025.102365_bib21","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1158\/1538-7445.AM2020-651","article-title":"Chemotherapy induces a transient senescence-like state capable of initiating AML recurrence","volume":"80","author":"Li","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102365_bib22","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41375-022-01789-6","article-title":"Single-cell analysis reveals the chemotherapy-induced cellular reprogramming and novel therapeutic targets in relapsed\/refractory acute myeloid leukemia","volume":"37","author":"Li","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2025.102365_bib23","doi-asserted-by":"crossref","first-page":"7309","DOI":"10.1002\/jcb.28005","article-title":"BET inhibitors reduce cell size and induce reversible cell cycle arrest in AML","volume":"120","author":"Zhang","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.xcrm.2025.102365_bib24","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/s41568-022-00450-9","article-title":"Exploiting senescence for the treatment of cancer","volume":"22","author":"Wang","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2025.102365_bib25","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.3324\/haematol.2022.281915","article-title":"Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells","volume":"108","author":"Jia","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.xcrm.2025.102365_bib26","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/s42003-021-02257-0","article-title":"When dormancy fuels tumour relapse","volume":"4","author":"Santos-de-Frutos","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.xcrm.2025.102365_bib27","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nbt.1607","article-title":"Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML","volume":"28","author":"Saito","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2025.102365_bib28","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41408-018-0087-2","article-title":"Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia","volume":"8","author":"Laverdi\u00e8re","year":"2018","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.xcrm.2025.102365_bib29","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1182\/blood-2016-10-696039","article-title":"Therapeutic targeting of acute myeloid leukemia stem cells","volume":"129","author":"Pollyea","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102365_bib30","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1182\/blood.V87.9.3563.bloodjournal8793563","article-title":"Flt3 Ligand Induces Proliferation of Quiescent Human Bone Marrow CD34+CD38- Cells and Maintains Progenitor Cells In Vitro","volume":"87","author":"Shah","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102365_bib31","doi-asserted-by":"crossref","DOI":"10.1186\/s12934-021-01559-6","article-title":"Expression of a recombinant FLT3 ligand and its emtansine conjugate as a therapeutic candidate against acute myeloid leukemia cells with FLT3 expression","volume":"20","author":"Zhang","year":"2021","journal-title":"Microb. Cell Fact."},{"key":"10.1016\/j.xcrm.2025.102365_bib32","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2025.102365_bib33","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.coi.2016.03.002","article-title":"Immunoglobulin isotype knowledge and application to Fc engineering","volume":"40","author":"Brezski","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.xcrm.2025.102365_bib34","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-020-00876-4","article-title":"How to select IgG subclasses in developing anti-tumor therapeutic antibodies","volume":"13","author":"Yu","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2025.102365_bib35","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s12032-024-02549-5","article-title":"Progression and perspectives in disease modeling for Juvenile myelomonocytic leukemia","volume":"42","author":"Fu","year":"2024","journal-title":"Med. Oncol."},{"key":"10.1016\/j.xcrm.2025.102365_bib36","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40164-023-00379-1","article-title":"Leukemogenic SHP2 mutations lead to erythropoietin independency of HCD-57 cells: a novel model for preclinical research of SHP2-mutant JMML","volume":"12","author":"Zhao","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2025.102365_bib37","doi-asserted-by":"crossref","first-page":"4668","DOI":"10.1111\/jcmm.15132","article-title":"Wild-type FLT3 and FLT3 ITD exhibit similar ligand-induced internalization characteristics","volume":"24","author":"Kellner","year":"2020","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.xcrm.2025.102365_bib38","doi-asserted-by":"crossref","first-page":"9228","DOI":"10.1073\/pnas.84.24.9228","article-title":"RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes","volume":"84","author":"Janssen","year":"1987","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2025.102365_bib39","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1158\/1541-7786.MCR-22-0109","article-title":"Proliferation and Self-Renewal Are Differentially Sensitive to NRASG12V Oncogene Levels in an Acute Myeloid Leukemia Cell Line","volume":"20","author":"Kurata","year":"2022","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102365_bib40","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.3324\/haematol.2018.209460","article-title":"FLT3 ligand plasma levels in acute myeloid leukemia","volume":"104","author":"Pierre","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.xcrm.2025.102365_bib41","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1182\/blood-2010-01-266742","article-title":"FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo","volume":"117","author":"Sato","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102365_bib42","doi-asserted-by":"crossref","first-page":"17049","DOI":"10.1038\/cddiscovery.2017.49","article-title":"Tumor cell senescence response produces aggressive variants","volume":"3","author":"Yang","year":"2017","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.xcrm.2025.102365_bib43","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nature22993","article-title":"Tracing the origins of relapse in acute myeloid leukaemia to stem cells","volume":"547","author":"Shlush","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102365_bib44","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1158\/0008-5472.CAN-18-3437","article-title":"Tumor Cell Escape from Therapy-Induced Senescence as a Model of Disease Recurrence after Dormancy","volume":"79","author":"Saleh","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102365_bib45","doi-asserted-by":"crossref","first-page":"4827","DOI":"10.1038\/s41467-022-32552-1","article-title":"A new gene set identifies senescent cells and predicts senescence-associated pathways across tissues","volume":"13","author":"Saul","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102365_bib46","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.devcel.2015.10.011","article-title":"Lineage-Specific Profiling Delineates the Emergence and Progression of Naive Pluripotency in Mammalian Embryogenesis","volume":"35","author":"Boroviak","year":"2015","journal-title":"Dev. Cell"},{"key":"10.1016\/j.xcrm.2025.102365_bib47","doi-asserted-by":"crossref","first-page":"5975","DOI":"10.1038\/onc.2008.213","article-title":"Critical pathways in cellular senescence and immortalization revealed by gene expression profiling","volume":"27","author":"Fridman","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.xcrm.2025.102365_bib48","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1371\/journal.pbio.0060301","article-title":"Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor","volume":"6","author":"Coppe","year":"2008","journal-title":"PLoS Biol."},{"key":"10.1016\/j.xcrm.2025.102365_bib49","article-title":"Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML","volume":"4","author":"Popescu","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.xcrm.2025.102365_bib50","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1200\/JCO.2011.36.9868","article-title":"Impact of FLT3 Internal Tandem Duplication on the Outcome of Related and Unrelated Hematopoietic Transplantation for Adult Acute Myeloid Leukemia in First Remission: A Retrospective Analysis","volume":"30","author":"Brunet","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102365_bib51","doi-asserted-by":"crossref","first-page":"6987","DOI":"10.1182\/blood-2011-03-340273","article-title":"FLT3\/ITD AML and the law of unintended consequences","volume":"117","author":"Levis","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102365_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217446","article-title":"FLT3 inhibitors induce p53 instability, driven by STAT5\/MDM2\/p53 competitive interactions in acute myeloid leukemia","volume":"611","author":"Pei","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.xcrm.2025.102365_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100850","article-title":"Hematopoietic versus leukemic stem cell quiescence: Challenges and therapeutic opportunities","volume":"50","author":"O'Reilly","year":"2021","journal-title":"Blood Rev."},{"key":"10.1016\/j.xcrm.2025.102365_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103710","article-title":"Leukemic stem cells as a target for eliminating acute myeloid leukemia: Gaps in translational research","volume":"175","author":"Khaldoyanidi","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.xcrm.2025.102365_bib55","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jim.2009.06.008","article-title":"ELDA: Extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays","volume":"347","author":"Hu","year":"2009","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.xcrm.2025.102365_bib56","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41580-021-00404-3","article-title":"Cell cycle control in cancer","volume":"23","author":"Matthews","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.xcrm.2025.102365_bib57","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/sj.leu.2402459","article-title":"Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and\/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers","volume":"16","author":"Matsui","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2025.102365_bib58","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0301-472X(98)00041-1","article-title":"Priming with G-CSF effectively enhances low-dose Ara-C-induced in vivo apoptosis in myeloid leukemia cells","volume":"27","author":"Bai","year":"1999","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.xcrm.2025.102365_bib59","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1007\/s00277-024-05791-z","article-title":"Impact of cladribine, cytarabine, and G-CSF (CLAG) as a bridging therapy prior to allogeneic hematopoietic stem cell transplantation in relapsed or refractory acute myeloid leukemia","volume":"103","author":"Cui","year":"2024","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.xcrm.2025.102365_bib60","doi-asserted-by":"crossref","first-page":"8984","DOI":"10.1038\/s41598-018-27174-x","article-title":"A platform of BRET-FRET hybrid biosensors for optogenetics, chemical screening, and in vivo imaging","volume":"8","author":"Komatsu","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2025.102365_bib61","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/nmeth.4045","article-title":"Fluorescent indicators for simultaneous reporting of all four cell cycle phases","volume":"13","author":"Bajar","year":"2016","journal-title":"Nat. Methods"},{"key":"10.1016\/j.xcrm.2025.102365_bib62","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2025.102365_bib63","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/ng1180","article-title":"PGC-1\u03b1-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes","volume":"34","author":"Mootha","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2025.102365_bib64","series-title":"Antibody-Drug Conjugates","first-page":"267","article-title":"Drug-to-Antibody Ratio (DAR) by UV\/Vis Spectroscopy","author":"Chen","year":"2013"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125004380?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125004380?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T23:13:06Z","timestamp":1788563586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379125004380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":64,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2666379125004380"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102365","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FLT3L-based drug conjugate effectively targets chemoresistant leukemia stem cells in acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102365","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102365"}}